Boc-Dap-Tra single crystal, important component of DUO-5, and its preparation method and application

By preparing Boc-Dap-Tra single crystal, the problems of low purity of starting raw materials and difficult to control the absolute configuration of chiral center in DUO-5 synthesis are solved, and the accurate definition of compound structure and high purity production are achieved, which improves the drug safety and effectiveness.

CN117903034BActive Publication Date: 2024-11-05LEVENA BIOPHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410054100.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-15
Publication Date
2024-11-05
Estimated Expiration
2044-01-15

AI Technical Summary

Technical Problem

The synthesis steps of existing DUO-5 are complex, the starting material is low purity, and the absolute configuration control of chiral center is difficult, which affects the safety and effectiveness of drug conjugates.

Method used

By preparing Boc-Dap-Tra single crystals, the absolute configuration of the chiral center is defined as {C23(S), C26(R), C28(R), C30(S)}, and the single crystals are cultured by solvent volatilization method, which belongs to Orthogonal crystal system, P212121 space group, an anhydrous form, consisting of only one Boc-Dap-Tra molecule.

Benefits of technology

It simplifies the difficulty of confirming the structure of the compound, improves the purity of raw materials and crystal form, reduces production costs, and improves the quality of raw materials of DUO-5.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117903034B_ABST
    Figure CN117903034B_ABST
Patent Text Reader

Abstract

The present invention relates to a Boc-Dap-Tra single crystal, an important constituent fragment of DUO-5, and a preparation method and application thereof. The Boc-Dap-Tra single crystal has an absolute configuration of a chiral center in a molecule of {C23(S), C26(R), C28(R), C30(S)}. The difficulty and correctness of the structural confirmation of the compound in the research and development process are greatly simplified, and a strong supporting basis is provided for the absolute configuration of DUO-5; and the preparation method thereof is simple to operate, the prepared crystal form has high purity, and the particle size distribution is uniform, which reduces the production cost and improves the purity of the raw materials for producing DUO-5.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of single crystal preparation, and relates to a Boc-Dap-Tra single crystal, in particular to a Boc-Dap-Tra single crystal, an important component fragment of DUO-5, and a preparation method and application thereof. Background Art

[0002] Antibody drug conjugate (ADC) is a new type of anti-tumor drug. Its principle is to connect cytotoxins to antibodies through linkers. Through the recognition of specific antigens on the surface of cancer cells by antibodies, ADCs enter cancer cells through endocytosis, thereby transporting cytotoxins to the target site, achieving the purpose of targeted treatment of malignant tumors. Compared with traditional small molecule anti-tumor drugs, ADCs are more specific and effective because they can use the targeted recognition of antibodies and the high activity of toxins.

[0003] ADC consists of three parts: antibodies, cytotoxins and linkers. Cytotoxins are delivered to tumor tissues through antibodies, achieving targeted delivery of toxins and thus exerting anti-tumor activity.

[0004] Duostatin 5 (DUO-5) is a cytotoxin designed based on Aplysia toxin, as shown in the following formula. It has a very effective anti-mitotic effect. It inhibits cell division by blocking the polymerization of tubulin to achieve anti-tumor purposes. It can be used as an effective cytotoxin in ADCs and is coupled to HER-2 monoclonal antibodies through a protease-cleavable linker for the treatment of HER-2-positive advanced metastatic breast cancer.

[0005]

[0006] Currently, the commercially available DUO-5 is an amorphous solid, and there is no literature or patent reporting on the crystals of free DUO-5. The synthesis steps of DUO-5 are long, the starting materials are of low purity, and there are multiple chiral centers. The absolute configuration is difficult to control, the chiral purity is low, and the absolute configuration characterization is difficult, which affects the safety and effectiveness of drug conjugates. Therefore, it is of great significance to improve the purity of the starting materials and determine the absolute configuration of their chiral carbons. Summary of the invention

[0007] In order to solve the above technical problems, the first object of the present invention is to provide a single crystal of Boc-Dap-Tra, an important constituent fragment of DUO-5, the absolute configuration of the chiral center in its molecule is: {C23(S), C26(R), C28(R), C30(S)}.

[0008] Optimally, it belongs to the orthorhombic system, space group P212121.

[0009] Furthermore, its unit cell parameter 1 is { α=90°, β=90°, γ=90°, }.

[0010] Optimally, it is in an anhydrous crystalline form, its asymmetric unit is composed of only one Boc-Dap-Tra molecule and its crystal structure does not contain crystal water molecules or other solvent molecules.

[0011] Another object of the present invention is to provide a method for preparing single crystals of Boc-Dap-Tra, an important constituent fragment of the above-mentioned DUO-5, by culturing single crystals of Boc-Dap-Tra samples by solvent volatilization.

[0012] Optimally, the method specifically includes the following steps:

[0013] The Boc-Dap-Tra sample is mixed with a solvent to form a suspension, the filtrate is collected by filtration and sealed, and a small hole is opened at the sealing port after sealing to allow the solvent to evaporate at room temperature; the solvent is an alcohol solvent or an ether solvent.

[0014] Furthermore, the alcohol solvent is a mixture of one or more selected from C1 to C5 monohydric alcohols, and the ether solvent is a mixture of one or more selected from C1 to C7 ethers.

[0015] Furthermore, the alcohol solvent is methanol, n-propanol or isopropanol, preferably methanol; the ether solvent is diethyl ether, 2-methyltetrahydrofuran or methyl tert-butyl ether, preferably 2-methyltetrahydrofuran.

[0016] Optimally, the concentration of the Boc-Dap-Tra sample in the solvent is 1 mg / ml to 50 mg / ml, preferably 20-40 mg / ml.

[0017] Furthermore, the concentration of the Boc-Dap-Tra sample in methanol is 40 mg / ml, and the solvent is evaporated at room temperature to precipitate crystals; the concentration of the Boc-Dap-Tra sample in 2-methyltetrahydrofuran is 40 mg / ml, and the solvent is evaporated at room temperature to precipitate crystals.

[0018] Another object of the present invention is to provide a use of the above-mentioned DUO-5 important constituent fragment Boc-Dap-Tra single crystal as a standard or reference substance.

[0019] Compared with the prior art, the present invention has the following beneficial effects: the Boc-Dap-Tra single crystal, an important constituent fragment of DUO-5 of the present invention, greatly simplifies the difficulty and correctness of the structure confirmation of the compound in the development process by limiting the absolute configuration of the chiral center, and provides a strong supporting basis for the absolute configuration of DUO-5; and its preparation method is simple to operate, the prepared crystal form has high purity and uniform particle size distribution, which reduces the production cost and improves the purity of the raw materials for producing DUO-5. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 is the HPLC spectrum of the Boc-Dap-Tra sample of the present invention;

[0021] Figure 2 is the LCMS spectrum of the Boc-Dap-Tra sample of the present invention;

[0022] Figure 3 is the H-NMR spectrum of the Boc-Dap-Tra sample of the present invention;

[0023] Figure 4 This is a PLM photo of the Boc-Dap-Tra single crystal of the present invention;

[0024] Figure 5 Schematic diagram of the asymmetric unit of the Boc-Dap-Tra single crystal sample;

[0025] Figure 6 Schematic diagram of the stacking structure of molecules in the single crystal structure model of the Boc-Dap-Tra single crystal sample (observed along the a-axis);

[0026] Figure 7 Schematic diagram of the unit cell of the single crystal structure model of the Boc-Dap-Tra single crystal sample;

[0027] Figure 8 This is the overlay of the calculated XRPD of the single crystal structure model of the Boc-Dap-Tra single crystal sample and the measured XRPD of the Boc-Dap-Tra single crystal sample. DETAILED DESCRIPTION

[0028] The preparation of the Boc-Dap-Tra single crystal of the important component fragment of DUO-5 of the present invention starts with an amorphous Boc-Dap-Tra sample, and a rod-shaped single crystal sample is obtained by slowly evaporating the solvent in the solution. Single crystal x-ray diffraction characterization shows that the single crystal belongs to the orthorhombic system, P212121 space group, and its unit cell parameters are: { α=90°, β=90°, γ=90°, }. The single crystal structure analysis shows that the asymmetric unit of the crystal structure is composed of only one Boc-Dap-Tra molecule, and the crystal structure does not contain any crystal water molecules or other solvent molecules. This indicates that the single crystal of the compound Boc-Dap-Tra obtained by cultivation is anhydrous. Based on the single crystal structure data of the compound Boc-Dap-Tra, the stereochemical structure of the compound Boc-Dap-Tra was confirmed, and the absolute configuration of the chiral center in the molecule is {C23 (S), C26 (R), C28 (R), C30 (S)}.

[0029] The synthesis steps of the aforementioned Boc-Dap-Tra sample are as follows:

[0030] 1.1 Step 1: Boc-Dap-Tra sample synthesis

[0031] In a 250 ml three-necked flask, 8.27 g (28.78 mmol, 1.1 eq) of Boc-Dap and 160 ml of DCM were added. Under nitrogen protection, the mixture was cooled to 3° C. in an ice bath. 12.74 g (3.0 eq) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EDCl and 3.0 g (1.0 eq) of 1-hydroxy-benzo-triazole HOBt were added. 5.75 g (2.0 eq) of N,N-diisopropylethylamine DIPEA was added dropwise and the temperature was controlled and stirred for 20 minutes. Then 10.0 g (1.0 eq) of Tra was added and the mixture was reacted at room temperature for 1 hour. The reaction was complete when detected by HPLC. The mixture was washed once with 250 ml of water, washed twice with 250 ml of saturated sodium bicarbonate aqueous solution, and washed once with 250 ml of water. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to obtain 14.0 g of a yellow solid. The solid was dissolved in 500 ml of dichloromethane, added dropwise to 1000 ml of n-heptane, stirred for 1 hour, filtered, and dried to obtain 10.9 g of a light yellow solid.

[0032] 1.2 Step 2 Boc-Dap-Tra reverse phase purification

[0033] Take 5.0 g of the above light yellow solid, add 4.0 ml of DMF, 4.0 ml of acetonitrile and 4.0 ml of purified water, dissolve, and use Biotage medium pressure column machine for gradient elution and C18 reverse phase column preparation and purification;

[0034] Purification conditions: 80g C18 reverse phase column, wavelength: 220nm, flow rate: 50ml / min; mobile phase: A: water, B: acetonitrile. Collect the product and mix, add 200ml dichloromethane for extraction, wash the organic phase with 50ml water 3 times, dry with anhydrous sodium sulfate, filter, and concentrate to obtain 1.32g of white solid, HPLC: 99.65%, LCMS: 683.38[M+H] +, H-NMR is consistent with the structure (such as Figures 1 to 3 shown).

[0035] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0036] Example 1

[0037] This embodiment provides a Boc-Dap-Tra single crystal, an important component of DUO-5, and a preparation method thereof, as follows:

[0038] Weigh 20.2 mg of the compound Boc-Dap-Tra sample and place it in a 3 mL glass vial. Add 0.5 mL of methanol solvent and perform appropriate ultrasonic oscillation to form a sample suspension. Then filter using a syringe and a syringe filter head (0.45 μm PTFE filter membrane), and transfer the filtrate to a clean 4 mL single crystal bottle. Use a PE single crystal bottle stopper to seal the bottle, and then pierce a small hole in the stopper. Finally, place the system in a room temperature fume hood to allow the room temperature solvent to evaporate slowly. After one day of solvent evaporation, rod-shaped crystal samples were observed to precipitate in the system, such as Figure 4 shown.

[0039] The rod-shaped single crystal sample was photographed, X-ray diffracted, and the single crystal structure was analyzed. Figure 4-Figure 8 and Table 1. Among them, Figure 4 This is a photo of the Boc-Dap-Tra single crystal sample PLM. Figure 5 Schematic diagram of the asymmetric unit of the Boc-Dap-Tra single crystal sample. Figure 6 Schematic diagram of the stacking structure of molecules in the single crystal structure model of the Boc-Dap-Tra single crystal sample (observed along the a-axis). Figure 7 This is a schematic diagram of the unit cell of the single crystal structure model of the Boc-Dap-Tra single crystal sample. Figure 8 This is the overlay of the calculated XRPD of the single crystal structure model of the Boc-Dap-Tra single crystal sample and the measured XRPD of the Boc-Dap-Tra single crystal sample.

[0040] Figure 5 Schematic diagram of the asymmetric unit of the Boc-Dap-Tra single crystal sample. Analysis shows that the asymmetric unit of the crystal is composed of only one Boc-Dap-Tra molecule, and the crystal structure does not contain any crystal water molecules or other solvent molecules. This indicates that the compound Boc-Dap-Tra single crystal is anhydrous.

[0041] In order to show the structural characteristics of the single crystal more clearly, Figure 7The unit cell diagram of the single crystal structure model shows that each unit cell of the single crystal structure contains 4 Boc-Dap-Tra molecules. Based on the single crystal structure data of the compound Boc-Dap-Tra obtained by analysis, it is confirmed that the stereochemical structure of the compound Boc-Dap-Tra is shown in Formula II The absolute configuration of the chiral center in the molecule is {C23(S), C26(R), C28(R), C30(S)}. Table 1 shows the crystallographic data and structural refinement parameters of the single crystal of compound Boc-Dap-Tra.

[0042] Table 1 Crystallographic data and structure refinement parameters of Boc-Dap-Tra single crystal

[0043]

[0044] Example 2

[0045] This embodiment provides a Boc-Dap-Tra single crystal, an important component of DUO-5, and a preparation method thereof, as follows:

[0046] Weigh 20.2 mg of the compound Boc-Dap-Tra starting sample and place it in a 3 mL glass vial. Add 0.5 mL of 2-methyltetrahydrofuran solvent and perform appropriate ultrasonic oscillation to form a sample suspension. Then filter using a syringe and a syringe filter head (0.45 μm PTFE filter membrane), and transfer the filtrate to a clean 4 mL single crystal bottle. Use a PE single crystal bottle stopper to seal, and then pierce a small hole in the stopper. Finally, place the system in a room temperature fume hood to slowly evaporate the solvent at room temperature. One day after the solvent evaporated, crystals were observed in the system to form clusters (not convenient for cutting for single crystal data collection).

[0047] Example 3

[0048] This embodiment provides a Boc-Dap-Tra single crystal, an important component of DUO-5, and a preparation method thereof, as follows:

[0049] Weigh 5.0 mg of the compound Boc-Dap-Tra starting sample and place it in a 3 mL glass vial. Add 0.5 mL of isopropanol solvent and perform appropriate ultrasonic oscillation to form a sample suspension. Then filter using a syringe and a syringe filter head (0.45 μm PTFE filter membrane), and transfer the filtrate to a clean 4 mL single crystal bottle. Use a PE single crystal bottle stopper to seal, and then pierce a small hole in the stopper. Finally, place the system in a room temperature fume hood to slowly evaporate the solvent at room temperature. After the solvent evaporated for several days, crystals were observed in the system to form clusters.

[0050] Example 4

[0051] This embodiment provides a Boc-Dap-Tra single crystal, an important component of DUO-5, and a preparation method thereof, as follows:

[0052] Weigh 3.0 mg of the compound Boc-Dap-Tra starting sample and place it in a 3 mL glass vial. Add 0.5 mL of methyl tert-butyl ether solvent and perform appropriate ultrasonic oscillation to form a sample suspension. Then filter using a syringe and a syringe filter head (0.45 μm PTFE filter membrane), and transfer the filtrate to a clean 4 mL single crystal bottle. Use a PE single crystal bottle stopper to seal, and then pierce a small hole in the stopper. Finally, place the system in a room temperature fume hood to slowly evaporate the solvent at room temperature. After the solvent evaporated for several days, crystals were observed in the system to form clusters.

[0053] Comparative Examples 1-12

[0054] Comparative Examples 1-12 are basically the same as those in Example 1, except for the type of solvent and the amount of material used. However, they are unable to precipitate crystals, as shown in Table 2.

[0055] Table 2 Single crystal growth parameters of comparative examples 1-4

[0056]

[0057]

[0058] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A method for preparing a single crystal of Boc-Dap-Tra, an important component of DUO-5, wherein the chemical formula of Boc-Dap-Tra, an important component of DUO-5, is The important component fragment of DUO-5, Boc-Dap-Tra single crystal, has the absolute configuration of the chiral center in its molecule: {C23 (S), C26 (R), C28 (R), C30 (S)}; It is characterized in that The method comprises the following steps: mixing the Boc-Dap-Tra sample with a solvent to form a suspension, filtering and collecting the filtrate and sealing, and after sealing, opening a small hole at the sealing port to volatilize the solvent at room temperature; the concentration of the Boc-Dap-Tra sample in the solvent is 1 mg / ml to 50 mg / ml; and the solvent is methanol.

2. The method for preparing the single crystal of Boc-Dap-Tra, an important constituent fragment of DUO-5, according to claim 1, is characterized in that: It belongs to the orthorhombic crystal system, space group P212121.

3. The method for preparing the single crystal of Boc-Dap-Tra, an important constituent fragment of DUO-5, according to claim 2, characterized in that: Its unit cell parameter 1 is α=90°, β=90°, γ=90°, 4. The method for preparing the single crystal of Boc-Dap-Tra, an important constituent fragment of DUO-5, according to claim 1, characterized in that: It is anhydrous crystalline, its asymmetric unit is composed of only one Boc-Dap-Tra molecule and its crystal structure does not contain crystal water molecules or other solvent molecules.

5. The method for preparing the single crystal of Boc-Dap-Tra, an important constituent fragment of DUO-5, as claimed in claim 1, characterized in that: The concentration of the Boc-Dap-Tra sample in the solvent was 20-40 mg / ml.